帕尼单抗诱发转移性结直肠癌患者的间质性肺疾病。
Panitumumab-induced interstitial lung disease in a case of metastatic colorectal cancer.
作者信息
Yamada Takeshi, Moriwaki Toshikazu, Matsuda Kenji, Yamamoto Yoshiyuki, Sugaya Akinori, Akutsu Daisuke, Murashita Tetsuya, Endo Shinji, Hyodo Ichinosuke
机构信息
Division of Gastroenterology, Tsukuba University Hospital, Ibaraki, Japan.
出版信息
Onkologie. 2013;36(4):209-12. doi: 10.1159/000349959. Epub 2013 Mar 18.
BACKGROUND
A Japanese postmarketing survey of panitumumab revealed that panitumumab-associated interstitial lung disease (ILD) occurred in approximately 1% (19/1767) of patients, causing death in 36.8% of these cases.
CASE REPORT
We report the case of a 60-year-old Japanese man who developed ILD associated with panitumumab therapy (third-line therapy) for metastatic sigmoid colon cancer involving the liver, lymph nodes, and lungs. 2 months after the initiation of panitumumab therapy, he developed a progressive nonproductive cough, dyspnea, and a fever, and was diagnosed with ILD. Intravenous pulse methylprednisolone treatment led to quick recovery. The patient had some risk factors for ILD associated with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors.
CONCLUSION
Further studies are required to elucidate the association between anti-EGFR antibodies and ILD.
背景
一项关于帕尼单抗的日本上市后调查显示，帕尼单抗相关的间质性肺病（ILD）发生在约1%（19/1767）的患者中，其中36.8%的病例导致死亡。
病例报告
我们报告了一名60岁日本男性的病例，他因转移性乙状结肠癌累及肝脏、淋巴结和肺部接受帕尼单抗治疗（三线治疗）时发生了ILD。帕尼单抗治疗开始2个月后，他出现进行性干咳、呼吸困难和发热，并被诊断为ILD。静脉注射甲基强的松龙脉冲治疗后迅速康复。该患者有一些与表皮生长因子受体（EGFR）-酪氨酸激酶抑制剂相关的ILD危险因素。
结论
需要进一步研究以阐明抗EGFR抗体与ILD之间的关联。
Zotero 插件